View Item 

Show simple item record

Higher Levels of Cystatin C Are Associated with Worse Cognitive Function in Older Adults with Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Cognitive Study
dc.contributor.authorYaffe, Kristineen_US
dc.contributor.authorKurella‐tamura, Manjulaen_US
dc.contributor.authorAckerson, Lynnen_US
dc.contributor.authorHoang, Tina D.en_US
dc.contributor.authorAnderson, Amanda H.en_US
dc.contributor.authorDuckworth, Marken_US
dc.contributor.authorGo, Alan S.en_US
dc.contributor.authorKrousel‐wood, Marieen_US
dc.contributor.authorKusek, John W.en_US
dc.contributor.authorLash, James P.en_US
dc.contributor.authorOjo, Akinloluen_US
dc.contributor.authorRobinson, Nancyen_US
dc.contributor.authorSehgal, Ashwini R.en_US
dc.contributor.authorSondheimer, James H.en_US
dc.contributor.authorSteigerwalt, Susanen_US
dc.contributor.authorTownsend, Raymond R.en_US
dc.date.accessioned2014-10-07T16:09:14Z
dc.date.availableWITHHELD_12_MONTHSen_US
dc.date.available2014-10-07T16:09:14Z
dc.date.issued2014-09en_US
dc.identifier.citationYaffe, Kristine; Kurella‐tamura, Manjula ; Ackerson, Lynn; Hoang, Tina D.; Anderson, Amanda H.; Duckworth, Mark; Go, Alan S.; Krousel‐wood, Marie ; Kusek, John W.; Lash, James P.; Ojo, Akinlolu; Robinson, Nancy; Sehgal, Ashwini R.; Sondheimer, James H.; Steigerwalt, Susan; Townsend, Raymond R. (2014). "Higher Levels of Cystatin C Are Associated with Worse Cognitive Function in Older Adults with Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Cognitive Study ." Journal of the American Geriatrics Society 62(9): 1623-1629.en_US
dc.identifier.issn0002-8614en_US
dc.identifier.issn1532-5415en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/108602
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherCognitionen_US
dc.subject.otherChronic Kidney Diseaseen_US
dc.subject.otherCystatin Cen_US
dc.titleHigher Levels of Cystatin C Are Associated with Worse Cognitive Function in Older Adults with Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Cognitive Studyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108602/1/jgs12986.pdf
dc.identifier.doi10.1111/jgs.12986en_US
dc.identifier.sourceJournal of the American Geriatrics Societyen_US
dc.identifier.citedreferenceBuschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974; 24: 1019 – 1025.en_US
dc.identifier.citedreferenceShlipak MG, Sarnak MJ, Katz R et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049 – 2060.en_US
dc.identifier.citedreferencePeralta CA, Shlipak MG, Judd S et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin‐to‐creatinine ratio and association with progression to end‐stage renal disease and mortality. JAMA 2011; 305: 1545 – 1552.en_US
dc.identifier.citedreferenceBhavsar NA, Appel LJ, Kusek JW et al. Comparison of measured GFR, serum creatinine, cystatin C, and beta‐trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis 2011; 58: 886 – 893.en_US
dc.identifier.citedreferenceKurella M, Chertow GM, Fried LF et al. Chronic kidney disease and cognitive impairment in the elderly: The Health, Aging, and Body Composition Study. J Am Soc Nephrol 2005; 16: 2127 – 2133.en_US
dc.identifier.citedreferenceKurella M, Chertow GM, Luan J et al. Cognitive impairment in chronic kidney disease. J Am Geriatr Soc 2004; 52: 1863 – 1869.en_US
dc.identifier.citedreferenceKurella M, Yaffe K, Shlipak MG et al. Chronic kidney disease and cognitive impairment in menopausal women. Am J Kidney Dis 2005; 45: 66 – 76.en_US
dc.identifier.citedreferenceFeldman HI, Appel LJ, Chertow GM et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and methods. J Am Soc Nephrol 2003; 14: S148 – S153.en_US
dc.identifier.citedreferenceYaffe K, Ackerson L, Tamura MK et al. Chronic kidney disease and cognitive function in older adults: Findings from the Chronic Renal Insufficiency Cohort Cognitive Study. J Am Geriatr Soc 2010; 58: 338 – 345.en_US
dc.identifier.citedreferenceErlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 1999; 59: 1 – 8.en_US
dc.identifier.citedreferenceAnderson A, Xie D, Tao K et al. Internal standardization of cystatin C measurements in the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol 2010; 21: 176A. ASN abstract 287.en_US
dc.identifier.citedreferenceTeng EL, Chui HC. The modified Mini‐Mental State (3MS) Examination. J Clin Psychiatry 1987; 48: 314 – 318.en_US
dc.identifier.citedreferenceReitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958; 8: 271 – 276.en_US
dc.identifier.citedreferenceWelsh KA, Butters N, Mohs RC et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994; 44: 609 – 614.en_US
dc.identifier.citedreferenceCoresh J, Astor BC, McQuillan G et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002; 39: 920 – 929.en_US
dc.identifier.citedreferenceSeliger SL, Siscovick DS, Stehman‐Breen CO et al. Moderate renal impairment and risk of dementia among older adults: The Cardiovascular Health Cognition Study. J Am Soc Nephrol 2004; 15: 1904 – 1911.en_US
dc.identifier.citedreferenceSlinin Y, Paudel ML, Ishani A et al. Kidney function and cognitive performance and decline in older men. J Am Geriatr Soc 2008; 56: 2082 – 2088.en_US
dc.identifier.citedreferenceTamura MK, Wadley V, Yaffe K et al. Kidney function and cognitive impairment in US adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Am J Kidney Dis 2008; 52: 227 – 234.en_US
dc.identifier.citedreferenceSeliger SL, Longstreth WT Jr, Katz R et al. Cystatin C and subclinical brain infarction. J Am Soc Nephrol 2005; 16: 3721 – 3727.en_US
dc.identifier.citedreferenceWada M, Nagasawa H, Kawanami T et al. Cystatin C as an index of cerebral small vessel disease: Results of a cross‐sectional study in community‐based Japanese elderly. Eur J Neurol 2010; 17: 383 – 390.en_US
dc.identifier.citedreferenceRajagopalan P, Refsum H, Hua X et al. Mapping creatinine‐ and cystatin C‐related white matter brain deficits in the elderly. Neurobiol Aging 2013; 34: 1221 – 1230.en_US
dc.identifier.citedreferenceSmith EE, Salat DH, Jeng J et al. Correlations between MRI white matter lesion location and executive function and episodic memory. Neurology 2011; 76: 1492 – 1499.en_US
dc.identifier.citedreferenceGhidoni R, Benussi L, Glionna M et al. Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment. J Alzheimers Dis 2010; 22: 985 – 991.en_US
dc.identifier.citedreferenceKestenbaum B, Rudser KD, de Boer IH et al. Differences in kidney function and incident hypertension: The Multi‐Ethnic Study of Atherosclerosis. Ann Intern Med 2008; 148: 501 – 508.en_US
dc.identifier.citedreferenceMuntner P, Winston J, Uribarri J et al. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med 2008; 121: 341 – 348.en_US
dc.identifier.citedreferenceGr Luc, Bard J‐M, Cl Lesueur et al. Plasma cystatin‐C and development of coronary heart disease: The PRIME Study. Atherosclerosis 2006; 185: 375 – 380.en_US
dc.identifier.citedreferenceSundelof J, Sundstrom J, Hansson O et al. Cystatin C levels are positively correlated with both a‐beta 42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. J Alzheimers Dis 2010; 21: 471 – 478.en_US
dc.identifier.citedreferenceSun B, Zhou Y, Halabisky B et al. Cystatin C‐cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 2008; 60: 247 – 257.en_US
dc.identifier.citedreferenceTizon B, Ribe EM, Mi W et al. Cystatin C protects neuronal cells from amyloid‐beta‐induced toxicity. J Alzheimers Dis 2010; 19: 885 – 894.en_US
dc.identifier.citedreferenceSastre M, Calero M, Pawlik M et al. Binding of cystatin C to Alzheimer's amyloid β inhibits in vitro amyloid fibril formation. Neurobiol Aging 2004; 25: 1033 – 1043.en_US
dc.identifier.citedreferenceShlipak MG, Wassel Fyr CL, Chertow GM et al. Cystatin C and mortality risk in the elderly: The Health, Aging, and Body Composition Study. J Am Soc Nephrol 2006; 17: 254 – 261.en_US
dc.identifier.citedreferencePeralta CA, Katz R, Sarnak MJ et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011; 22: 147 – 155.en_US
dc.identifier.citedreferenceKaeser SA, Herzig MC, Coomaraswamy J et al. Cystatin C modulates cerebral [beta]‐amyloidosis. Nat Genet 2007; 39: 1437 – 1439.en_US
dc.identifier.citedreferenceKaur G, Levy E. Cystatin C in Alzheimer's disease. Front Mol Neurosci 2012; 5: 79.en_US
dc.identifier.citedreferenceBugnicourt J‐M, Godefroy O, Chillon J‐M et al. Cognitive disorders and dementia in CKD: The neglected kidney‐brain axis. J Am Soc Nephrol 2013; 24: 353 – 363.en_US
dc.identifier.citedreferenceSarnak MJ, Katz R, Fried LF et al. Cystatin C and aging success. Arch Intern Med 2008; 168: 147 – 153.en_US
dc.identifier.citedreferenceYaffe K, Lindquist K, Shlipak MG et al. Cystatin‐C as a marker of cognitive function in elders: Findings from the Health ABC Study. Ann Neurol 2008; 63: 798 – 802.en_US
dc.identifier.citedreferenceSundelof J, Arnlov J, Ingelsson E et al. Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology 2008; 71: 1072 – 1079.en_US
dc.identifier.citedreferenceMaetzler W, Schmid B, Synofzik M et al. The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis 2010; 19: 937 – 942.en_US
dc.identifier.citedreferenceCathcart HM, Huang R, Lanham IS et al. Cystatin C as a risk factor for Alzheimer disease. Neurology 2005; 64: 755 – 757.en_US
dc.identifier.citedreferenceFinckh U, von der Kammer H, Velden J et al. Genetic association of a cystatin C gene polymorphism with late‐onset Alzheimer disease. Arch Neurol 2000; 57: 1579 – 1583.en_US
dc.identifier.citedreferenceHua Y, Zhao H, Lu X et al. Meta‐Analysis of the cystatin C (CST3) gene G73A Polymorphism and susceptibility to Alzheimer's disease. Int J Neurosci 2012; 122: 431 – 438.en_US
dc.identifier.citedreferenceDeng A, Irizarry MC, Nitsch RM et al. Elevation of Cystatin C in susceptible neurons in Alzheimer's disease. Am J Pathol 2001; 159: 1061 – 1068.en_US
dc.identifier.citedreferenceLevy EP, Sastre MP, Kumar AP et al. Codeposition of cystatin C with amyloid‐[beta] protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol 2001; 60: 94 – 104.en_US
dc.identifier.citedreferenceColl E, Botey A, Alvarez L et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29 – 34.en_US
dc.identifier.citedreferenceMenon V, Shlipak MG, Wang X et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007; 147: 19 – 27.en_US
dc.identifier.citedreferenceTangri N, Inker LA, Tighiouart H et al. Filtration markers may have prognostic value independent of glomerular filtration rate. J Am Soc Nephrol 2012; 23: 351 – 359.en_US
dc.identifier.citedreferenceShlipak MG, Katz R, Sarnak MJ et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237 – 246.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jgs12986.pdf
Size:
122.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.